ATLANTA--(BUSINESS WIRE)--Inhibitex, Inc. (NASDAQ: INHX), a biopharmaceutical company focused on developing products to treat and prevent serious infectious diseases, announced today, effective immediately, that it has received approval from the NASDAQ Listing Qualifications Staff to transfer the listing of its common stock from the NASDAQ Global Market to the NASDAQ Capital Market.
